Prestige Consumer Healthcare Inc. — Form 10-Q Summary
Business and period: Prestige develops, manufactures, markets and distributes over-the-counter healthcare products in North America and selected international markets. This fiscal second-quarter report covers the three and six months ended September 30, 2023; the fiscal year ends March 31.
Financial performance
| Metric | Three months ended September 30, 2023 | Six months ended September 30, 2023 |
|---|---|---|
| Total revenue | $286.3 million, down 1.0% | $565.6 million, down 0.1% |
| Gross profit / margin | $160.0 million / 55.9%, versus 55.7% | $314.7 million / 55.6%, versus 56.7% |
| Operating income | $88.3 million, up 4.6% | $173.4 million, up 1.2% |
| Net income | $53.6 million, up 5.0% | $106.8 million, up 0.5% |
| Diluted earnings per share | $1.07, versus $1.02 | $2.13, versus $2.11 |
| Operating cash flow | Not provided separately for the quarter | $110.5 million, versus $115.8 million |
Quarterly operating margin was approximately 30.8% versus 29.2%; six-month operating margin was approximately 30.7% versus 30.3%. Six-month advertising and marketing expense declined to $76.3 million from $83.8 million, while gross profit fell $6.4 million, primarily reflecting higher supply-chain costs and product mix, partly offset by pricing. Interest expense rose to $35.3 million for the six months from $32.3 million, as the average borrowing cost increased to 5.4% from 4.3% despite lower average indebtedness.
Liquidity, debt and capital allocation
- Cash was $60.1 million at September 30, 2023, compared with $58.5 million at March 31, 2023. Current assets were $388.2 million and current liabilities $129.7 million.
- Net cash provided by operating activities was $110.5 million; capital expenditures were $4.4 million. Cash used in financing was $107.7 million, including $85.0 million of term-loan repayments and $25.0 million of share repurchases.
- Debt principal totaled $1.275 billion ($1.263 billion net of unamortized debt costs): $600 million of 3.750% notes due 2031, $400 million of 5.125% notes due 2028, and $275 million of variable-rate term loans due 2028. The company had no revolver borrowings and $171.2 million of available borrowing capacity.
- The company reported compliance with its debt covenants and said it expects to remain compliant over the next 12 months. No common dividends had been declared or paid through September 30.
Changes, outlook and risks
- North American revenue declined 3.0% in the quarter and 0.8% for the half year; international revenue increased 12.6% and 4.6%, respectively. Women’s Health was a notable source of North American weakness; international growth included Women’s Health and Eye & Ear Care.
- Management said cash from operations and existing credit facilities should cover working capital and capital expenditures for the next 12 months, excluding acquisitions. The filing provides no specific revenue or earnings guidance.
- Management cited volatile economic conditions, inflation, rising interest rates, geopolitical uncertainty, changing shopping patterns, and possible shortages, shipping delays and supplier price increases. These factors had not materially harmed aggregate sales, earnings or liquidity to date, but could do so if conditions worsen.
- Walmart represented approximately 20.0% of six-month gross revenue; Amazon represented 10.3%. The company relies on third-party manufacturers and a primary third-party-managed U.S. distribution center.
- Variable-rate debt was $275 million. A 1 percentage-point rate increase would have raised pre-tax expense by approximately $1.6 million for the six-month period, holding other factors constant. A prior-year impairment review resulted in $48.8 million of goodwill and $321.4 million of intangible-asset charges; management reported no impairment indicators at September 30, 2023.
- Routine legal matters were not expected by management to materially affect the financial statements. The filing reported no material change in risk factors from the prior annual report.
Important facts for investors to verify
- Whether revenue trends, particularly North American Women’s Health and international category growth, persist in subsequent quarters.
- Whether gross-margin pressure from supply-chain costs and product mix moderates, and how reduced marketing spend affects brand performance.
- Debt-service sensitivity to interest rates, covenant headroom, and the pace of further debt repayment.
- Customer and supplier concentration, distribution continuity, and potential impacts of labor, sourcing or shipping disruptions.
- Whether brand performance or valuation assumptions lead to future impairment charges, given the substantial goodwill and intangible-asset balances.